X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (675) 675
cardiac & cardiovascular systems (589) 589
index medicus (547) 547
female (543) 543
male (543) 543
middle aged (487) 487
aged (475) 475
risk factors (311) 311
mortality (260) 260
abridged index medicus (246) 246
treatment outcome (242) 242
heart attacks (212) 212
cardiovascular (197) 197
acute coronary syndromes (196) 196
myocardial infarction (190) 190
percutaneous coronary intervention (164) 164
clopidogrel (160) 160
prospective studies (152) 152
registries (152) 152
care and treatment (151) 151
cardiovascular disease (148) 148
time factors (147) 147
stroke (142) 142
peripheral vascular disease (140) 140
coronary heart disease (130) 130
follow-up studies (128) 128
myocardial-infarction (123) 123
heart attack (119) 119
management (115) 115
aspirin (113) 113
cardiac patients (113) 113
medical and health sciences (112) 112
medicin och hälsovetenskap (112) 112
platelet aggregation inhibitors - therapeutic use (111) 111
acute myocardial-infarction (110) 110
prognosis (110) 110
myocardial infarction - therapy (108) 108
myocardial infarction - mortality (107) 107
thrombosis (106) 106
medicine, general & internal (105) 105
drug therapy (104) 104
risk assessment (104) 104
cardiovascular diseases (103) 103
cardiology (102) 102
electrocardiography (102) 102
outcomes (101) 101
patient outcomes (101) 101
risk (101) 101
coronary vessels (99) 99
angioplasty (97) 97
stents (97) 97
internal medicine (95) 95
aged, 80 and over (94) 94
double-blind method (90) 90
hemorrhage - chemically induced (90) 90
ticlopidine - analogs & derivatives (90) 90
drug therapy, combination (86) 86
patients (86) 86
therapy (86) 86
coronary artery disease (85) 85
acute coronary syndrome (84) 84
diabetes (82) 82
platelet aggregation inhibitors - administration & dosage (82) 82
ticagrelor (82) 82
prevention (81) 81
ischemia (78) 78
research (78) 78
clinical medicine (77) 77
adult (76) 76
clinical trials (76) 76
analysis (74) 74
guidelines (74) 74
klinisk medicin (71) 71
platelet aggregation inhibitors - adverse effects (71) 71
kardiologi (70) 70
cardiac and cardiovascular systems (68) 68
cardiology and cardiovascular medicine (68) 68
transluminal angioplasty (68) 68
intervention (67) 67
kaplan-meier estimate (66) 66
prevalence (65) 65
coronary angiography (64) 64
heart failure (64) 64
bleeding (63) 63
events (63) 63
usage (63) 63
trial (62) 62
acute coronary syndrome - drug therapy (61) 61
outpatients (61) 61
adenosine - analogs & derivatives (60) 60
health aspects (59) 59
atherosclerosis (58) 58
drug-eluting stents (58) 58
myocardial infarction - diagnosis (58) 58
secondary prevention (58) 58
studies (58) 58
anticoagulants (57) 57
myocardial infarction - drug therapy (57) 57
angioplasty, balloon, coronary (56) 56
medical research (56) 56
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1111) 1111
French (9) 9
Spanish (7) 7
Italian (2) 2
Polish (2) 2
German (1) 1
Portuguese (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European heart journal, ISSN 0195-668X, 03/2019, Volume 40, Issue 15, pp. 1211 - 1213
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A16658 - A16658
IntroductionLong-term treatment with ticagrelor 60 mg added to ASA reduces ischemic risk but increases bleeding in patients with prior MI.HypothesisClinical... 
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 04/2019, Volume 380, Issue 17, pp. 1678 - 1678
Journal Article
European Heart Journal, ISSN 0195-668X, 08/2012, Volume 33, Issue 15, pp. 1878 - 1885
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2155 - 2166
Patients who had received a drug-eluting stent and then dual antiplatelet therapy for 12 months were randomly assigned to 18 more months of therapy or aspirin... 
TRIALS | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | MULTICENTER | CLOPIDOGREL | TICAGRELOR | THROMBOSIS | RATIONALE | PREVENTION | ASPIRIN | CLINICAL-OUTCOMES | Piperazines - administration & dosage | Prasugrel Hydrochloride | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Aspirin - administration & dosage | Incidence | Time Factors | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Drug Therapy, Combination | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Drug-Eluting Stents | Drug Administration Schedule | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Myocardial Ischemia - therapy | Aged | Hemorrhage - chemically induced | Aggregation | Treatment outcome | Care and treatment | Usage | Blood platelets | Analysis | Drug-eluting stents | Dosage and administration | Cardiovascular diseases | Thrombosis | Health aspects | Blood clot | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Drug delivery | Patients | Bleeding | Clinical outcomes | Cerebrovascular system | Coronary vessels | Implants | Clopidogrel | Drug therapy | Stents
Journal Article
by White, Harvey D and Held, Claes and Stewart, Ralph and Tarka, Elizabeth and Brown, Rebekkah and Davies, Richard Y and Budaj, Anzej and Harrington, Robert A and Steg, P. Gabriel and Ardissino, Diego and Armstrong, Paul W and Avezum, Alvaro and Aylward, Philip E and Bryce, Alfonso and Chen, Hong and Chen, Ming-Fong and Corbalan, Ramon and Dalby, Anthony J and Danchin, Nicolas and de Winter, Robbert J and Denchev, Stefan and Diaz, Rafael and Elisaf, Moses and Flather, Marcus D and Goudev, Assen R and Granger, Christopher B and Grinfeld, Liliana and Hochman, Judith S and Husted, Steen and Kim, Hyo-Soo and Koenig, Wolfgang and Linhart, Ales and Lonn, Eva and López-Sendón, José and Manolis, Athanasios J and Mohler, Emile R and Nicolau, José C and Pais, Prem and Parkhomenko, Alexander and Pedersen, Terje R and Pella, Daniel and Ramos-Corrales, Marco A and Ruda, Mikhail and Sereg, Mátyás and Siddique, Saulat and Sinnaeve, Peter and Smith, Peter and Sritara, Piyamitr and Swart, Henk P and Sy, Rody G and Teramoto, Tamio and Tse, Hung-Fat and Watson, David and Weaver, W. Douglas and Weiss, Robert and Viigimaa, Margus and Vinereanu, gos and Zhu, Junren and Cannon, Christopher P and Wallentin, Lars and Steg, Ph Gabriel and Bucan, Olga and Elfström, Charlotta and Hegg, Lisa and Jarosz, Marie and Krug-Gourley, Sue and Rudman, Jerry and Collins, Rory and Anderson, Jeffrey and DeMets, David and Ganz, Peter and Sandercock, Peter and Weber, Michael and Fisher, Marian and Buhr, Kevin and Diegel, Scott and Schultz, Melissa and Mahaffey, Kenneth W and Alexander, John H and Al-Khatib, Sana and Baron, Tomasz and Bergström, Olle and Bushnell, Cheryl and Christersson, Christina and Eggers, Kai and Fredlund, Bengt-Olov and Hagström, Emil and Hijazi, Ziad and Örndahl, Lovisa Holm and James, Stefan K and Jernberg, Tomas and Johnston, Nina and Lopez, Renato D and Mehta, Rajena H and Newby, Kristin L and Nordmark, Örjan and Oldgren, Jonas and Roe, Matthew T and Saldéen, Katarina and Stenborg, Anna and ... and The STABILITY Investigators and STABILITY Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 18, pp. 1702 - 1711
Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease.... 
TRIAL | LIPOPROTEIN | MEDICINE, GENERAL & INTERNAL | THERAPY | ACTIVATING-FACTOR ACETYLHYDROLASE | OXIDIZED LDL | RISK | PHOSPHOLIPASE A | ATHEROSCLEROTIC PLAQUE | INHIBITOR | CLINICAL-OUTCOMES | Stroke - prevention & control | Double-Blind Method | Follow-Up Studies | Oximes - adverse effects | Phospholipase A2 Inhibitors - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Oximes - administration & dosage | Male | Coronary Artery Disease - drug therapy | Coronary Disease - mortality | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | Benzaldehydes - administration & dosage | Coronary Artery Disease - complications | Treatment Failure | Coronary Disease - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Prevention | Care and treatment | Ischemia | Dosage and administration | Research | Coronary heart disease | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Phospholipase A2 | Clinical trials | Myocardial ischemia | Cardiovascular disease | Angina | Preventive medicine | Coronary artery disease | Phospholipase | Arteriosclerosis | Death | Plasma levels | Drug therapy | Heart diseases | Plaques | Malalties cardiovasculars | Infart de miocardi | Malalties coronàries | Assaigs clínics de medicaments | Cardiovascular diseases | Drug testing | Coronary diseases | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9749, pp. 1320 - 1328
Summary Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the composite outcome of... 
Internal Medicine | ALLELE | MEDICINE, GENERAL & INTERNAL | INHIBITION | ANTAGONIST | PLATELET-AGGREGATION | STENT THROMBOSIS | OF-FUNCTION POLYMORPHISM | P-GLYCOPROTEIN EXPRESSION | PRASUGREL | PHARMACOGENETICS | TREATED PATIENTS | Ticlopidine - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Adenosine - adverse effects | Adenosine - therapeutic use | Ticlopidine - adverse effects | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Pharmacogenetics | Genotype | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Acute Coronary Syndrome - drug therapy | Phenotype | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Cytochrome P-450 CYP2C19 | Adenosine - analogs & derivatives | ATP Binding Cassette Transporter, Sub-Family B | Aged | Polymorphism, Single Nucleotide | Acute Coronary Syndrome - genetics | Care and treatment | Patient outcomes | Physiological aspects | Clopidogrel | Dosage and administration | Single nucleotide polymorphisms | Health aspects | Coronary heart disease | Studies | Heart attacks | Statistical analysis | Metabolites | Genetics | Drug therapy | Gene expression | Acute coronary syndromes | Myocardial infarction | Stroke | Single-nucleotide polymorphism | Arteries | Bleeding | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article